RenovoRx Must Show Center Growth Can Turn A Raised Guide Into Another Record

RenovoRx heads into its third-quarter report with an unusual problem for a small drug-delivery company: the bar it has to clear was set by management, not Wall Street. After raising its full-year revenue outlook in August and saying the current quarter was already tracking ahead of a record second quarter, the company now has to show that its RenovoCath commercial rollout is compounding rather than merely improving. The report, due after the close on November 5, is less about the size of the loss and more about whether the sales engine is gathering speed on schedule.

The consensus calls for revenue of about $1.1 million, nearly four times the roughly $0.3 million booked a year earlier and a step up from $0.9 million last quarter. Analysts expect a loss of $0.05 per share, an improvement of 37.5% from a year ago and roughly in line with the prior quarter. The more telling comparison is with guidance. Management lifted its 2026 revenue range to $3.75 million to $4.25 million from $3.0 million to $4.0 million, yet the full-year consensus sits near $3.13 million, below even the new low end. With first-half revenue of roughly $1.47 million, hitting the guided range requires about $2.3 million to $2.8 million in the second half. A $1.1 million third quarter would leave a fourth quarter of $1.2 million to $1.7 million to land inside the range, which looks achievable if adoption keeps its recent pace. In other words, the Street's annual number appears stale, and a quarter at or above consensus would likely force estimates higher.

The operating metric that matters most is active commercial centers. That count climbed from 12 in February to 16 in May and 21 by the end of June, with management targeting 36 or more by year-end. That target implies the company must add roughly 15 centers in two quarters, a faster clip than it has managed so far. A third-quarter count in the high 20s would validate the plan; anything stuck in the low 20s would raise doubts about the year-end goal and, by extension, the fourth-quarter revenue needed to meet guidance. The broader funnel, which grew to 63 centers, offers a read on whether that pipeline is still widening or simply being converted. Procedure volume, which passed 900 cumulative cases, and early follow-through on the first commercial use in sarcoma would show whether demand is broadening beyond pancreatic cancer.

The clinical story provides a supporting backdrop. TIGERPAC, the company's Phase 3 trial, closed enrollment in August with 78 of the 86 required events observed, and topline data is now expected in the second half of 2027. Confirmation that randomization is fully complete and that event accrual is progressing would further de-risk the timeline. Gross margin, which slipped to about 84% from 88% at the end of 2025, is worth monitoring, though management pointed to a next-generation device launching next year as a source of upside.

Cash is the counterweight. Reserves fell to $9.5 million at the end of June, with runway into the second half of 2027, while breakeven depends on reaching about $5 million in quarterly revenue by late 2027. A narrowing burn rate would make that gap easier to bridge without heavy dilution.

The market has leaned in. Shares are up about 24% since the last report, far ahead of a slightly lower S&P 500, and sentiment has turned less bearish. Still, at $1.39 the stock sits well below its post-earnings high of $2.59 and not far above its 200-day moving average of $1.10, suggesting enthusiasm has cooled from its peak. The verdict will rest on whether center activations are accelerating fast enough to make the raised guidance, and the 36-center goal, look credible.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.